Financial Data and Key Metrics Changes - Revenues for the first quarter were $641,000 compared to $237,000 in the same period the previous year, primarily due to revenues recognized from the collaboration agreement of Evogene's subsidiary, AgPlenus, with Corteva and from sales of Canonic's medical cannabis products in Israel [35] - Net loss for the first quarter of 2023 was $7 million compared to a net loss of $9.1 million in the same period in the previous year [36] - Consolidated cash as of March 31, 2023, was approximately $28.8 million, excluding the $10 million investment in Biomica received in April 2023 [75] Business Line Data and Key Metrics Changes - Lavi Bio's product, Drivers, is a microbiome seed treatment that enhances yield in North America across 10 million acres, with plans to broaden sales into Canadian and European markets [64] - AgPlenus is focusing on developing new herbicides and has seen interest in its product pipeline, particularly the APH1 candidate [66] - Canonic launched 6 new second-generation products in Israel and is expanding its sales model to include licensing agreements [13][95] Market Data and Key Metrics Changes - The initial target market for Lavi Bio's bio-fungicide product is valued at $200 million, with a second product targeting a $500 million market [11] - The castor market, particularly for biofuel, is rapidly growing, and Castera is positioned to be a key player in that market [69] Company Strategy and Development Direction - The company aims to enter new business relationships for product development leveraging its tech engines, focusing on enhancing the robustness and attractiveness of its AI-driven tech engines [62][70] - The long-term plan includes realizing value by spinning out or IPO-ing one or more subsidiaries, depending on market conditions [99] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the demand for products exceeding supply and plans to ramp up production for the expected increase in sales next year [93] - The company is aware of the need to improve investor relations and plans to allocate more resources to this area [131] Other Important Information - The company has no bank debt and aims to maintain self-sufficiency financially for the foreseeable future [20][70] - Recent external investments in subsidiaries like Lavi Bio and Biomica validate the significant inherent value within these entities [71] Q&A Session Summary Question: What is the expected production for Lavi Bio in 2024? - Management indicated that they expect a few hundred tons a year in 2024, which will be inventory for sale [80] Question: How is the company addressing the stock price issue? - Management acknowledged the need for better communication with the market and plans to enhance investor relations activities [46][131] Question: Can you provide more details on the Phase I clinical trial for Biomica? - Management confirmed that approximately 12 patients are expected to be enrolled in the Phase I study, with several already participating [107]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F | ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | OR | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended December 31, 2022 | | | OR | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | | ☐ | SHELL COMPANY REPORT PURSUANT TO SECTION ...

Exhibit 99.2 EVOGENE LTD. 13 Gad Feinstein St., Park Rehovot P.O.B. 4173, Ness Ziona, 7414003, Israel PROXY STATEMENT 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS This Proxy Statement is being furnished in connection with the solicitation of proxies on behalf of the Board of Directors, or the Board, of Evogene Ltd., to which we refer as Evogene or the Company, to be voted at the 2023 Annual General Meeting of Shareholders of the Company, or the Meeting, and at any adjournment thereof, pursuant to the Notice ...

Financial Data and Key Metrics Changes - As of the end of Q3 2022, the company has a consolidated cash position of $38 million, which is expected to last until late 2024 [7][29] - The consolidated cash usage for Q3 2022 was approximately $7.3 million, with a cash burn rate for the first nine months of the year at $25.9 million [30][31] - Revenues for Q3 2022 were $466,000, compared to $151,000 in the same period the previous year, primarily due to a collaboration agreement [32] Business Line Data and Key Metrics Changes - Lavie Bio received a $10 million investment from ICL, which is expected to enhance its product pipeline and commercialization efforts [9][12] - Biomica is progressing in its Phase 1 clinical trial for BMC128, with the third patient dosed recently [15] - Canonic launched its second-generation cannabis products with higher THC levels and has initiated a licensing agreement with GroVida for commercialization in Europe [18][21] Market Data and Key Metrics Changes - The medical cannabis market in Europe is estimated at approximately €400 million, indicating significant growth potential [21] - The global demand for biofuel is increasing, which may enhance the market for castor oil derived from castor beans [25] Company Strategy and Development Direction - The company aims to strengthen its financial position by pursuing fundraising for its subsidiaries and establishing collaborations that provide non-dilutive payments [8][28] - The focus will shift towards existing activities and commercial aspects rather than new initiatives, particularly in the case of Canonic [38] Management's Comments on Operating Environment and Future Outlook - The management acknowledges the volatility in financial markets, especially in the biotech sector, but expresses confidence in navigating these challenges [6] - The company is optimistic about the potential for fundraising in the short to mid-term for subsidiaries like Biomica and Canonic [41] Other Important Information - The company has no bank debts and is working to reduce its cash burn in 2023 [29][31] - A leadership change at Canonic has been announced, with Eyal Ronen appointed as the new CEO effective January 1, 2023 [23] Q&A Session Summary Question: Can you elaborate on your business plan and fundraising opportunities? - The CEO indicated that Biomica is well-positioned for near-term fundraising, with other subsidiaries like Canonic and AgPlenus expected to follow [38] Question: What can we expect in the spring 2023 update for Biomica? - The focus will be on safety results from the clinical trial, with potential indications of efficacy being disclosed if observed [39][40] Question: How are you understanding the financial resource requirements for each subsidiary? - Each subsidiary is establishing clear targets and budgets for 2023 and 2024, with the company confident in its ability to fund ongoing activities [41]

Financial Data and Key Metrics Changes - As of June 30, 2022, the company maintained approximately $35.3 million in consolidated cash, cash-related accounts, bank deposits, and marketable securities, with no bank debt [18] - Revenues for Q2 2022 were $312,000, compared to $135,000 in the same period the previous year, primarily due to initial sales of Lavie-Bio's Thrivus product and Canonic products in the Israeli market [20] - The net loss for Q2 2022 was $9.8 million, compared to a net loss of $6.9 million in the same period the previous year [22] Business Line Data and Key Metrics Changes - Lavie-Bio's Thrivus product saw initial sales contributing to revenue, with plans for expanded production in 2023 [20][13] - R&D expenses for Q2 2022 were $5.4 million, up from $5 million in the same period the previous year, driven by increased activities in Lavie-Bio and Biomica's Phase 1 trial [20] - Business Development expenses rose to approximately $1 million in Q2 2022 from $700,000 in the same period the previous year, reflecting recruitment efforts [21] Market Data and Key Metrics Changes - The strategic collaboration with ICL, which includes a $10 million investment in Lavie-Bio, aims to develop novel bio-stimulants, enhancing agricultural sustainability and productivity [8][9] - The company is targeting to launch new varieties of Canonic products in the second half of 2022, addressing demand for high THC [34] Company Strategy and Development Direction - The company aims to leverage its technology engines through dedicated subsidiaries, with a focus on attracting high-value partners and investors [16] - The strategy includes ensuring each subsidiary has its own financial resources, reducing reliance on Evogene's budget over time [31] - The company is exploring new activities that can benefit from its technology, with a focus on collaborations that can inject cash into the company [31] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of the recent strategic collaborations and investments as evidence of the value being created by Lavie-Bio and Biomica [5] - The company is optimistic about the potential for increased revenue from Canonic products in the second half of the year, with new product launches planned [34] - Management emphasized the need to balance cash on hand while expanding technology applications into other fields [30] Other Important Information - The company is under no obligation to update forward-looking statements unless required by law, and it cautions that actual results may differ from anticipated results due to various factors [3][4] - The investment from ICL is structured under a SAFE agreement, allowing Lavie-Bio to continue its development and growth [22] Q&A Session Summary Question: Discussion on Lavie-Bio's collaboration with ICL - Management indicated that the collaboration focuses on bio-stimulants and that there is significant value in working with a fertilizer company like ICL, which has extensive experience in the field [25][26] Question: Importance of FDA advisory committee meeting for Biomica - Management acknowledged the significance of understanding FDA expectations for microbiome-based products but deferred specific details to another team member [27][29] Question: Balancing cash on hand while expanding technology applications - Management reiterated the goal for subsidiaries to have their own financial resources and mentioned ongoing discussions with investors for additional funding [30][31] Question: Valuation parameters for the $10 million investment in Lavie-Bio - Management could not disclose specific details of the SAFE contract but expressed satisfaction with the deal's terms and its positive implications for shareholders [33] Question: Granularity on revenue from Lavie-Bio and Canonic - Management expects increased revenue from Canonic in the second half of the year, with new product launches planned [34]

Evogene Ltd. (NASDAQ:EVGN) Q1 2022 Results Conference Call May 26, 2022 9:00 AM ET Company Participants Ofer Haviv - CEO, President & Chairman Elran Haber - CEO, Biomica Yaron Eldad - CFO Conference Call Participants Kristen Kluska - Cantor Fitzgerald Nathan Weinstein - Aegis Capital Brett Reiss - Janney Montgomery Scott Brian Wright - ROTH Operator Ladies and gentlemen, thank you for standing by. Welcome to Evogene's First Quarter 2022 Results Conference Call. All participants are present in a listen-only ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Ordinary shares, par value NIS 0.02 per share EVGN Nasdaq Stock Market LLC FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 1 ...

Evogene Ltd. (NASDAQ:EVGN) Q3 2021 Earnings Conference Call November 17, 2021 9:00 AM ET Â Company Participants Ofer Haviv - President, Chief Executive Officer Arnon Heyman - Chief Executive Officer, Canonic Dorit Kreiner - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Nathan Weinstein - Aegis Capital Brett Reiss - Janney Montgomery Scott Brian Wright - Roth Capital Partners Operator Ladies and gentlemen, thank you for standing by. Welcome to EvogeneÂ's third quarte ...

| --- | --- | --- | --- | |-------|-------|-------|-------| | | | | | | | | | | Forward Looking Statement This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 19 ...

Financial Data and Key Metrics Changes - Evogene reported consolidated cash of approximately $65.4 million as of June 30, 2021, with a cash usage of approximately $11.3 million in the first half of 2021, and $5.7 million in the second quarter [45][46] - Revenues for the second quarter of 2021 were $0.1 million, down from $0.3 million in the same period the previous year [49] - R&D expenses increased to $5.0 million in Q2 2021 from $3.9 million in Q2 2020, attributed to product development activities [50] - Operating loss for Q2 2021 was $7.4 million compared to $5.2 million in Q2 2020 [51] Business Line Data and Key Metrics Changes - Biomica is preparing for its first-in-man proof-of-concept study in immuno-oncology and reported significant pre-clinical data for its candidate BMC128 [27][28] - Canonic is establishing its production and marketing infrastructure for medical cannabis products, with plans for a product launch in Israel in 2022 [31][32] - AgPlenus is making progress in collaboration with Corteva to develop novel herbicides and has achieved positive results in its internal herbicide program [35][36] - Lavie Bio is advancing its product pipeline with a focus on biostimulants and bio fungicides, expecting to launch its lead biostimulant LAV211 in 2022 [38][40] Market Data and Key Metrics Changes - The medical cannabis market in Israel is growing rapidly, with government approval for cannabis companies to export products, opening new markets for Canonic [87] - The market for innovative life-science products is characterized by high failure rates and long commercialization timelines, but Evogene's technology aims to mitigate these risks [21][22] Company Strategy and Development Direction - Evogene's strategy focuses on unlocking the value of its subsidiaries by potentially turning them into public companies, allowing for independent valuations [24][25] - The company aims to utilize advanced computational biology to enhance product development and reduce time-to-market [14][20] - The vision is to change how life science companies develop products, increasing success probabilities while reducing costs [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the advancements of subsidiaries towards commercialization and the potential for significant market opportunities [61][62] - The company is cautious about cash burn rates and aims to ensure that funding aligns with strategic goals [97][98] Other Important Information - The company has a strong financial position with no bank debt and is exploring ways to facilitate independent valuations of its subsidiaries [45][49] - The transition in leadership with Sarit Firon as the new Chairperson is expected to bring new energy and direction to the company [9][10] Q&A Session Summary Question: What are the initial market opportunities for the upcoming products? - Management indicated that they are in discussions with local distributors and expect significant revenue from the second year of product launches [54][56] Question: Why is the company considering turning subsidiaries into public companies now? - The management believes that several subsidiaries are advancing towards commercialization and that independent valuations will benefit shareholders [60][62] Question: How does the company view the potential for additional product pipelines beyond the main programs? - Management confirmed that each subsidiary has a promising product pipeline beyond what has been disclosed, and they are exploring additional opportunities [66][68] Question: What is the expected cash burn for next year? - Management expects cash burn to be managed carefully, with potential collaborations providing funding for ongoing activities [99][100]